Management of hypertriacylglycerolaemia from the point view of newest guidelines of The Endocrine Society
Authors:
Peter Jackuliak; Miriam Avramovová; Juraj Payer
Authors‘ workplace:
V. interná klinika Lekárskej fakulty UK a UNB, Nemocnica Ružinov, Bratislava, prednosta prof. MUDr. Juraj Payer, CSc.
Published in:
Forum Diab 2013; 2(2): 140-145
Category:
Overview
One of the major modifiable risk factor of atherosclerosis is atherogenic dyslipidemia characterized by hypertriglyceridemia, low levels of HDL-cholesterol and the presence of small dense LDL particles. Various recommendations are dedicated to management of disorders of lipid metabolism. In September 2012 The Endocrine Society released its recommendations to the management of hypertriglyceridemia.
Key words:
atherosclerosis – atherogenic dyslipidemia – dyslipoproteinemia – hypertriglyceridemia
Sources
1. Berglund L, Brunzell JD, Goldberg AC (eds) et al (Endocrine society). Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2012; 97(9): 2969–2989.
2. Reiner Z, Catapano AL, De Backer G (eds) et al (European Association for Cardiovascular Prevention & Rehabilitation). ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2011; 32(14): 1769–1818.
3. Filipová S, Mikeš Z, Dukát A et al. Aktualizácia lipidového konsenzu-2. Cardiol 2006; 15(6): 313–316.
4. Krahulec B. Obezita a niektoré faktory prostredia podporujúce vznik metabolického syndrómu. Cardiol 2005; 14(4): 161–165.
5. Fábryová Ľ. Manažment aterogénnej dyslipidémie pri metabolickom syndróme. Via pract 2007; 4(Suppl 4): 13–18.
6. Atkins D, Best D, Briss PA et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328(7454): 1490–1497.
7. Murad MH, Hazem A, Coto-Yglesias F et al. The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis. BMC endocr disord 2012; 12.2. Dostupné z DOI: <http://doi:10.1186/1472–6823–12–2>.
8. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52(2): 1210–1214.
9. Sniderman AD, Blank D, Zakarian R et al. Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula. Clin Biochem 2003; 36(7): 499–504.
10. Swiglo BA, Murad MH, Schünemann HJ et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab 2008; 93(3):666–673.
11. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008; 118(10): 993–1001.
12. Sanderson SL, Iverius PH, Wilson DE. Successful hyperlipemic pregnancy. JAMA 1991; 265(14): 1858–1860.
13. Carr MC, Knopp RH, Brunzell JD et al. Effect of raloxifene on serum triglycerides in women with a history of hypertriglyceridemia while on oral estrogen therapy. Diabetes Care 2005; 28(7):1555–1561.
14. Retnakaran R, Connelly PW, Goguen J. Unmasking of type III hyperlipoproteinemia by hypothyroidism: a dramatic illustration of altered lipoprotein metabolism in a postpartum woman. Endocr Pract 2005; 11(6): 394–398.
15. Brunzell JD, Ayyobi AF. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med 2003; 115 (Suppl 8a):24s-28s.
16. Alberti KG, Zimmet P, Shaw J (for the Epidemiology task force Consensus Group). The metabolic syndrome – a new worldwide definition. Lancet 2005; 366(9491): 1059–1062.
17. Garg A, Agarwal AK. Lipodystrophies: disorders of adipose tissue biology. Biochim Biophys Acta 2009; 1791(6): 507–513.
18. Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am 1994; 78(1):117–141.
19. Brinton EA. Effects of ethanol intake on lipoproteins and atherosclerosis. Curr Opin Lipidol 2010; 21(4): 346–351.
20. Veerkamp MJ, de Graaf J, Hendriks JC et al. Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a five-year follow-up study. Circulation 2004; 109(24): 2980–2985.
21. Austin MA, McKnight B, Edwards KL et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study. Circulation 2000; 101: 2777–2782.
22. Brunzell JD, Deeb SS. Familial lipoprotein lipase deficiency, apoC-II deficiency, and hepatic lipase deficiency. In: Scriver CR, Beaudet Al, Sly Ws, Valle D (eds). The metabolic basis of inherited disease. 8th ed. McGraw-Hill: New York 2001: 2789–2816.
23. Genest Jr J, Bard JM, Fruchart JC et al. Familial hypoalphalipoproteinemia in premature coronary artery disease. Arterioscler Thromb 1993; 13(12):1728–1737.
24. Mahley RW, Huang Y, Rall Jr SC. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res 1999; 40(11): 1933–1949.
25. Grundy SM, Cleeman JL, Daniels SR (eds) et al (American Heart Association; National Heart, Lung, and Blood Institute). Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 2005; 112(17): 2735–2752.
26. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med 2011; 9:48. Dostupné z DOI: <http://doi:10.1186/1741–7015–9-48>.
27. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 2003; 77(5): 1146–1155.
28. Graham TE. Exercise, postprandial triacylglyceridemia, and cardiovascular disease risk. Can J Appl Physiol 2004; 29(6): 781–799.
29. The BIP Study Group 2000 secondary prevention by raising Hdl cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate infarction Prevention (BIP) study. Circulation 2000; 102(1): 21–27.
30. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9,795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366(9500): 1849–1861.
31. Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345(22): 1583–1592.
32. Hu FB, Bronner L, Willett WC et al. Fish and omega-3 fatty acid intake and risk for coronary heart disease in women. JAMA 2002; 287(14): 1815–1821.
33. Sharma M, Ansari MT, Abou-Setta AM et al. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med 2009; 151(9): 622–630.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Forum Diabetologicum
2013 Issue 2
Most read in this issue
- Diabetic neuropathy: clinical features and contemporary possibilities of diagnostics and treatment
- Management of hypertriacylglycerolaemia from the point view of newest guidelines of The Endocrine Society
- Diabetic nephropathy: epidemiology and diagnosis
- Diabetic foot: epidemiological data and current topical treatment options